Why BioPhorum’s modern microbial methods evaluation roadmap is a foundation for success

28 July 2022
Fill Finish

Modern microbial methods and advanced technologies can provide significant benefits to biopharmaceutical companies, including enhanced sensitivity, cost and time savings, and continuous monitoring support.

Yet, despite these benefits and the extensive regulatory guidance available, their adoption is still not common. This is often because the challenges of assessing new technologies can add to a lack of understanding of the initial evaluation and implementation process. For example, a common oversight is not using a wide range of internal stakeholders early in the evaluation process.

This situation resulted in a new collaboration of industry working groups, including the BioPhorum Alternative and Rapid Micro Methods Bio-fluorescent Particle Counters (BFPC) team, which joined forces to support the awareness and adoption of modern microbial methods.

The Modern Microbial Methods (M3) collaboration has now written an article Initial Evaluation Roadmap for Modern Microbial Methods, which outlines the high-level topics, the questions to ask, and which internal stakeholders should be involved in an evaluation. It breaks down the process into four steps:

  1. The initial technology assessment
  2. Data and compliance risk
  3. Cost considerations
  4. Overall instrument evaluation.

Published by the Parenteral Drug Association, the article is aimed at a broad audience, including decision-makers who may have limited experience with evaluating and implementing modern microbial methods.

“I really value the collaboration across the industry to progress in areas of new technology adoption,” said Miriam Guest, Principal Microbiologist, New Modalities & Parenteral Development, AstraZeneca, UK. “The discussions that take place are an incredible opportunity to learn from industry peers. We’re all at different stages of the journey in various technology areas, and open collaboration is certainly a key enabler to transformation.”

Respond to issues quickly

The benefits of these modern methods apply across the microbiological control strategy. For example, they may help enhance your data integrity, process robustness, process understanding, and let you quickly respond to drifts in real-time, rather than waiting several days to discover a problem through traditional microbiological techniques.

Traditional methods can offer a fit-for-purpose solution to quality assurance but may have some limitations. As products evolve and patient reach expands, more technologies are becoming available to enhance awareness and decrease the time to a result. These new technologies also improve the current state of limited data available during the microbial review of manufacturing environments, processes, and products.

But to do all of this successfully, you need a robust evaluation process.

The hurdles of adopting modern microbial methods may seem large, so you must understand the limitations of current methods and assess the risks before adopting your new method. You can then mitigate those risks when developing your implementation plan for the new technique and adopt a clear framework to reduce the obstacles.

This is why the roadmap can significantly minimize your challenges and give you a foundation for success. As well as BioPhorum Alternative and Rapid Micro Methods BFPC team, the M3 collaboration includes the Kilmer Community Rapid Microbiology Methods Group, the Online Water Bioburden Analyzer (OWBA) Working Group and the Process and Environmental Monitoring Meth

Microbes In Petri Dish
A nine-step framework for evaluating alternative adventitious agent testing
Blood Cells
A nine-step approach for NAT-based mycoplasma detection
Colourful Bateria In Petri Dishes
Reducing human error through automated colony counting systems
Adding Liquid To Petri Dish
How successfully implementing alternative sterility tests can achieve a ~50% reduced incubation time
abstract yellow and green patterns
Is it time we revisit regulatory expectation that we obtain microbial identifications when using a non-growth-based monitoring method?

Advanced Therapy Medicinal Products

Advanced Therapy Medicinal Products support the quest for better and faster development of cell, gene and RNA therapies​ through connecting therapy developers, contract manufacturing, and testing organizations to gain an understanding and respond to the challenges faced by the advanced therapeutics industry.

Development Group

Development Group accelerates and improves the development process of biopharmaceutical medicines for the benefit of the patient. Replacing isolation with collaboration by providing a “safe” space where subject matter experts can work on sharing solutions and best practice on emerging industry trends, implementation of new technologies and common issues whilst ensuring their intellectual property and confidentiality is protected.

Drug Substance

Drug Substance advances excellence in drug substance manufacturing and testing, acting as an industry voice to accelerate technology adoption, implement post-approval change more rapidly and increase confidence in maintaining compliance.

Fill Finish

Fill Finish accelerates development and acceptance of sustainable world-class filling and packaging operations for drug product which meets the future needs of patients. Through innovative solutions resulting from the sharing of expertise, we can overcome common performance challenges and deliver on quality and regulatory compliance.

Information Technology

Information Technology accelerates digital maturity across the ​global pharmaceutical manufacturing industry.


BioPhorum Quality provides a dedicated, safe space for quality professionals from biomanufacturers and contract organizations to coalesce and enhance effective collaboration to address shared industry challenges.


Regulatory CMC brings leaders together who have a common goal – to improve access to medicines through innovation in the Regulatory ecosystem. It provides a dedicated space for strategic leadership and a coordinated industry voice, to move from divergence to convergence.

Supply Chain to Patient

Supply Chain to Patient transforms the performance of global pharmaceutical clinical and commercial outbound supply chains through industry collaboration by creating transparent patient-centric, resilient and agile E2E supply chains, that consistently deliver high-quality medicines ensuring an uninterrupted supply to patients.

Supply Partner

Supply Partner is a trusted advisory group and collaboration that is the engine for driving change across the global industry for all things relevant to the inbound supply chain. Addressing the challenges of complexity, resilience, cost, sustainability, and innovation.


Sustainability enables the industry’s transition to a low carbon, circular future – supporting members to improve patient health while respecting the planet. We activate multi-disciplinary teams drawn from our network to deliver environmental sustainability improvements across the value chain.

Technology Strategy

Technology Strategy acts as one voice of the industry to define strategy, accelerate technology transformation and support technology translation and adoption. With a purpose of enabling the future state of flexible, resilient, sustainable end-to-end biomanufacturing.

An industry perspective on understanding AAV capsid content variants
Needle On Yellow Background
An intercompany perspective on practical experiences of predicting, optimizing and analyzing high concentration biologic therapeutic formulations
The Drug Substance 2.0 Strategic Value Framework
Coloured dots on teal, next to vial
BioPhorum’s holistic approach to container closure integrity
Magnifying glass over a tablet all coloured blue
Digital Plant Maturity Model 3.0
Inaugural BioPhorum Quality face to face – get involved
The next step in building regulatory as a capability to enable strategic innovation across the BioPhorum community
Delivering a Cell and Gene Therapy Outbound Supply Chain Pathway for the Industry
DNA and Earth on blue background
A vision for the biopharmaceutical industry’s inbound supply chain
A major milestone – a harmonized approach to product carbon footprint data
Technology Roadmap V 2.0
BioPhorum Technology Roadmapping roadmap vision 2.0


Documents including best practices, vision statements and peer reviewed papers to help you take value back to your business.


Discussing all aspects of the biopharmaceutical industry, from digitization and knowledge management to raw materials, supply chain, sustainability and more. Learn from the perspectives of those at the forefront of the industry.


BioPhorum Connect is our podcast series that keeps you up to date with the latest news and trends in the biopharmaceutical industry. From experienced professionals to thought leaders, these podcasts bring you the insights and perspectives of experts from around the world.


A variety of resources including design tools and user requirement specifications to help you improve and streamline your business processes.

Benchmarks and Surveys

Research conducted among the BioPhorum membership providing evidence to support change and identify best practice.

Browse all

Access a variety of free tools and papers and other resources designed to provide you with up-to-date information and insights to help you make informed decisions and maximize your success. Access our resources today and start making improving and streamlining your business processes.

Bioreactivity testing in single-use system biomanufacturing
Bioreactivity testing in single-use system biomanufacturing
Bioreactivity testing in single-use system biomanufacturing
Magnifying glass over a tablet all coloured blue
Digital Plant Maturity Model 3.0
Bioreactivity testing in single-use system biomanufacturing